Orion Pharma
As of the edition of 20 October 2026, Orion Pharma runs 7 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Orion Pharma was acquired.
- ORION PHARMA: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Total | 7 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexmedetomidine | none listed | 9 |
| Tamoxifen | none listed | 0 |
| Levodopa | none listed | 4 |
| Carbidopa anhydrous | none listed | 2 |
| Levosimendan | none listed | 0 |
| Entacapone | none listed | 1 |
| Toremifene | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Orion Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.